Thrombospondin-1 regulates the normal prostate in vivo through angiogenesis and TGF-beta activation.
Castration experiments in rodents show that the stromal vasculature is critical to the androgen-mediated prostate growth regulation. However, the role of angiogenesis inhibitors, such as thrombospondin-1 (TSP-1), in this process is unclear. TSP-1 is a multifunctional glycoprotein that can function as a potent angiogenesis inhibitor and an in vivo activator of latent transforming growth factor-beta (TGF-beta) in some tissues. On the basis of these observations, we hypothesized that TSP-1 regulated androgen withdrawal-induced prostate regression and that this process was mediated not only through antiangiogenic activity but also through TGF-beta activation. To test this, we evaluated angiogenic activity in human prostate epithelial and stromal cells treated with androgens and hypoxia in vitro. TSP-1 knockout mice were characterized to investigate the in vivo functions of TSP-1. In vitro, we found that androgens and hypoxia differentially regulated TSP-1 and angiogenic activity. Androgens stimulated normal epithelial cell, but inhibited normal stromal cell, angiogenic activity. Conversely, hypoxia stimulated stromal while inhibiting epithelial activity. Thus, in vivo, net angiogenic activity must reflect cellular interactions. And, we found that media conditioned by epithelial cells grown under normoxic conditions stimulated stromal cell angiogenic activity, and if epithelial cells were grown under hypoxic conditions, stromal activity was further increased. TSP-1 levels, however, were unchanged. In vivo, TSP-1 loss in a mouse model led to prostate epithelial hyperplasia by 3 months of age with only a modest stromal effect. Androgens suppressed TSP-1 as expression increased after castration both in normal mouse prostate and in human prostate cancer tissues. In addition, TSP-1 expression corresponded to increased TGF-beta activation in mouse tissues, specifically in the stromal compartment. These data show a critical role for TSP-1 in prostate epithelial and stromal growth regulation through angiogenic inhibition and activation of latent TGF-beta. Therefore, loss of TSP-1 during tumorigenesis would eliminate two barriers to cancer progression.
Fitchev
Philip P
PP
Department of Surgery, NorthShore University HealthSystem Research Institute, Evanston, IL 60201, USA.
Wcislak
Susan M
SM
Lee
Chung
C
Bergh
Anders
A
Brendler
Charles B
CB
Stellmach
Veronica M
VM
Crawford
Susan E
SE
Mavroudis
Constantine D
CD
Cornwell
Mona L
ML
Doll
Jennifer A
JA
D000728:Androgens / Q000172:deficiency*; D000818:Animals; D002277:Carcinoma / Q000503:physiopathology; D002460:Cell Line; D013196:Dihydrotestosterone; D004847:Epithelial Cells / Q000378:metabolism; D006801:Humans; D006965:Hyperplasia; D000860:Hypoxia / Q000503:physiopathology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018919:Neovascularization, Physiologic; D009919:Orchiectomy; D010641:Phenotype; D011467:Prostate / Q000473:pathology / Q000502:physiology*; D011471:Prostatic Neoplasms / Q000503:physiopathology; D017154:Stromal Cells / Q000502:physiology; D019700:Thrombospondin 1 / Q000502:physiology*; D016212:Transforming Growth Factor beta / Q000378:metabolism*
D000728:Androgens; D019700:Thrombospondin 1; D016212:Transforming Growth Factor beta; D013196:Dihydrotestosterone
Expert Opin Ther Targets. 2009 Feb;13(2):227-34
19236240
Expert Opin Ther Targets. 2009 Feb;13(2):219-25
19236239
Science. 1988 Dec 9;242(4884):1412-5
2849206
J Endocrinol. 2008 Jan;196(1):11-9
18180313
Endocrinology. 1998 Feb;139(2):451-6
9449610
Clin Cancer Res. 1997 Dec;3(12 Pt 1):2507-11
9815654
Endocrinology. 1998 Nov;139(11):4672-8
9794479
Urol Res. 1999 Jun;27(3):174-9
10422818
Cell Death Differ. 2005 Jun;12(6):649-58
15818399
Cell. 1998 Jun 26;93(7):1159-70
9657149
J Cell Biochem. 2001;81(3):437-44
11255226
Cancer. 1997 Feb 15;79(4):772-9
9024715
Prostate. 1997 Sep 15;33(1):38-45
9294625
Prostate. 2007 Feb 15;67(3):255-67
17192876
Endocrinology. 2004 Oct;145(10):4507-12
15231711
Int J Mol Med. 2005 Jan;15(1):49-56
15583827
Cell Mol Life Sci. 2008 Mar;65(5):700-12
18193162
Cancer Gene Ther. 2000 Dec;7(12):1537-42
11228532
J Biol Chem. 1994 Oct 28;269(43):26783-8
7929414
Endocrinology. 1991 Dec;129(6):3187-99
1954898
Biochem Biophys Res Commun. 1998 Oct 9;251(1):287-90
9790948
Clin Cancer Res. 2001 Jan;7(1):81-8
11205922
Endocrinology. 1993 Jan;132(1):169-78
8419121
Nat Med. 2003 Jun;9(6):774-80
12740569
BJU Int. 2002 Feb;89(3):303-9
11856116
Prostate. 1998 Aug 1;36(3):201-6
9687993
Proc Natl Acad Sci U S A. 1990 Sep;87(17):6624-8
1697685
Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10820-5
9724788
Cancer Res. 2005 Jan 1;65(1):300-8
15665307
Am J Pathol. 1999 Sep;155(3):841-51
10487979
J Cell Physiol. 1996 Jan;166(1):231-9
8557772
Prostate. 2001 Dec 1;49(4):293-305
11746276
Prostate. 2003 Sep 15;57(1):57-65
12886524
Urol Res. 1997;25(5):309-14
9373910
Eur Urol. 1996;30(2):191-200
8875200
J Cell Biol. 1993 Jul;122(2):497-511
7686555
Prostate. 1999 Mar 1;38(4):268-77
10075006
J Clin Invest. 1998 Mar 1;101(5):982-92
9486968
Cancer. 1999 Apr 15;85(8):1822-7
10223578